Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
521.00
0.00 (0.00%)
At close: Jun 27, 2025, 4:00 PM
524.00
+3.00 (0.58%)
After-hours: Jun 27, 2025, 7:50 PM EDT
Regeneron Pharmaceuticals Employees
Regeneron Pharmaceuticals had 15,106 employees as of December 31, 2024. The number of employees increased by 1,656 or 12.31% compared to the previous year.
Employees
15,106
Change (1Y)
1,656
Growth (1Y)
12.31%
Revenue / Employee
$932,457
Profits / Employee
$297,849
Market Cap
55.05B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 15,106 | 1,656 | 12.31% |
| Dec 31, 2023 | 13,450 | 1,599 | 13.49% |
| Dec 31, 2022 | 11,851 | 1,483 | 14.30% |
| Dec 31, 2021 | 10,368 | 1,245 | 13.65% |
| Dec 31, 2020 | 9,123 | 1,023 | 12.63% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
REGN News
- 1 day ago - Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025 - GlobeNewsWire
- 3 days ago - Regeneron Pharmaceuticals Stock May Be Worth Buying Again - Rating Upgrade - Seeking Alpha
- 4 days ago - Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization - GlobeNewsWire
- 8 days ago - Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease - WSJ
- 8 days ago - Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid - GlobeNewsWire
- 8 days ago - Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP) - GlobeNewsWire
- 11 days ago - Regeneron declines to make higher bid for 23andMe after Wojcicki's $305 million offer - Reuters
- 13 days ago - Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study - GlobeNewsWire